Itraconazole

Generic Name: Itraconazole

Brand Names: Sporanox, Tolsura

Drug Type: Small Molecule

Chemical Formula: C_₃₅H_₃₈Cl_₂N_₈O_₄

CAS Number: 84625-61-6

Unique Ingredient Identifier: 304NUG5GF4

Background: One of the triazole antifungal agents that inhibits cytochrome P-450-dependent enzymes resulting in impairment of ergosterol synthesis. It has been used against histoplasmosis, blastomycosis, cryptococcal meningitis & aspergillosis.

Indication: For the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: pulmonary and extrapulmonary blastomycosis, histoplasmosis, aspergillosis, and onychomycosis.

Associated Conditions: Aspergillosis, Blastomycosis, Chromoblastomycosis, Coccidioidal meningitis, Esophageal Candidiasis, Fungal Infections, Fungal skin infection, Histoplasmosis, Onychomycosis, Oropharyngeal Candidiasis, Paracoccidioidomycosis, Penicillium marneffei infection, Pulmonary coccidioides, Sporotrichosis, Vulvovaginal Candidiasis, Disseminated Other specified protozoal diseases

Associated Therapies: -

Clinical Trials

A Study to Investigate the Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of PF-06700841 in Healthy Participants

Phase 1

Completed

Conditions: Heathy Participants

Interventions: Drug: PF-06700841
Drug: Itraconazole

First Posted Date: 2019-09-16

Last Posted Date: 2020-01-30

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT04090047

Locations: 🇺🇸
Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States

Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer

Phase 2

Recruiting

Conditions: Gastroesophageal Junction Adenocarcinoma
Esophagus Squamous Cell Carcinoma
Esophagus Adenocarcinoma

Interventions: Drug: Itraconazole

First Posted Date: 2019-07-15

Last Posted Date: 2021-11-04

Lead Sponsor: Dallas VA Medical Center

Target Recruit Count: 78

Registration Number: NCT04018872

Locations: 🇺🇸
Dallas VA Medical Center, Dallas, Texas, United States

A Study of LY3154885 in Healthy Participants

Phase 1

Terminated

Conditions: Healthy

Interventions: Drug: Placebo - Capsule
Drug: LY3154885 - Capsule
Drug: LY3154885 - Tablet
Drug: Itraconazole

First Posted Date: 2019-07-10

Last Posted Date: 2024-03-12

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 36

Registration Number: NCT04014361

Locations: 🇺🇸
Covance, Dallas, Texas, United States

A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 1323495 in the Blood

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1323495
Drug: Itraconazole

First Posted Date: 2019-07-08

Last Posted Date: 2024-02-22

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 14

Registration Number: NCT04011241

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

Study to Investigate the Effect of Rifampin and Itraconazole on the Action of Pamiparib in Participants With Cancer

Phase 1

Completed

Conditions: Solid Tumor

Interventions: Drug: pamiparib 60 mg
Drug: pamiparib 20 mg
Drug: pamiparib
Drug: rifampin
Drug: itraconazole

First Posted Date: 2019-06-21

Last Posted Date: 2024-10-26

Lead Sponsor: BeiGene

Target Recruit Count: 25

Registration Number: NCT03994211

Locations: 🇬🇪
Arensia Exploratory Medicine Llc, Tbilisi, Georgia
🇵🇱
Szpital Luxmed, Warszawa, Poland
🇸🇰
Summit Clinical Research, Sro, Bratislava, Slovakia

and more 1 locations

Study to Evaluate the Effect of Multiple Doses of Itraconazole and Rifampin on the Single-Dose Pharmacokinetics of Mitapivat Sulfate (AG-348) in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: rifampin
Drug: itraconazole
Drug: mitapivat sulfate

First Posted Date: 2019-06-19

Last Posted Date: 2019-10-23

Lead Sponsor: Agios Pharmaceuticals, Inc.

Target Recruit Count: 28

Registration Number: NCT03991312

Locations: 🇺🇸
Celerion, Inc, Tempe, Arizona, United States

A Study to Investigate the Effects of Itraconazole on the Pharmacokinetics of BMS-986256 in Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: BMS-986256
Drug: Itraconazole

First Posted Date: 2019-05-15

Last Posted Date: 2020-02-25

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 15

Registration Number: NCT03950960

Locations: 🇺🇸
PRA Health Sciences - Lenexa, Lenexa, Kansas, United States

A Study to Evaluate the Effect of Itraconazole on JNJ-56136379 in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: JNJ-56136379
Drug: Itraconazole

First Posted Date: 2019-05-10

Last Posted Date: 2019-11-27

Lead Sponsor: Janssen Sciences Ireland UC

Target Recruit Count: 16

Registration Number: NCT03945539

Locations: 🇧🇪
Clinical Pharmacology Unit, Merksem, Belgium

A Study to Evaluate Drug-Drug Interaction of TAK-788 With Itraconazole and Rifampin in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: TAK-788
Drug: Itraconazole
Drug: Rifampin

First Posted Date: 2019-04-26

Last Posted Date: 2020-08-21

Lead Sponsor: Millennium Pharmaceuticals, Inc.

Target Recruit Count: 24

Registration Number: NCT03928327

Locations: 🇺🇸
Celerion, Tempe, Arizona, United States

A Study of Itraconazole in the Management of Superficial Fungal Infections in India

Phase 4

Terminated

Conditions: Mycoses

Interventions: Drug: Itraconazole

First Posted Date: 2019-04-22

Last Posted Date: 2021-09-01

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 40

Registration Number: NCT03923010

Locations: 🇮🇳
Yenepoya Medical College, Mangalore, India
🇮🇳
Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh, India
🇮🇳
Sri Ramachandra Medical Centre, Chennai, India

and more 1 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy